For over 25 years, ABR has served the global pharmaceutical and biotechnology industries with world-class testing service, careful attention to quality and industry-leading turnaround time. The team of scientists at ABR is dedicated to providing accurate, timely, and precise results, while ensuring a high degree of customer service. ABR continues to design and develop virus detection protocols and other assays to meet evolving needs and changing regulations.
ABR’s virus assays satisfy United States 9th Code of Federal Regulation (9CFR), European Medicines Agency (EMA/EMEA), CVMP and CPMP regulations. Additionally, ABR operates under the principles of Good Laboratory Practice (GLP) as defined in the Twenty-first Code of Federal Regulations (21CFR), Part 58. In order to provide more service for customers, ABR has recently developed assays for mycoplasma by USDA-9CFR requirements as well as species of origin and IgG level tests. More assays and other regulatory compliance methods are under development. ABR also has the capability to customize studies for clients' needs in ever changing regulatory environments.